CAS 945614-12-0

Pexmetinib

Description:

Pexmetinib is a small molecule inhibitor primarily targeting the mitogen-activated protein kinase (MAPK) pathway, specifically the MEK enzyme. It is designed to interfere with the signaling pathways that promote cell proliferation and survival, making it a candidate for cancer therapy, particularly in tumors with specific genetic mutations. Pexmetinib has shown potential in clinical trials for treating various malignancies, including those with mutations in the RAS or RAF genes. The compound is characterized by its ability to selectively inhibit MEK1 and MEK2, which are crucial components in the MAPK signaling cascade. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are essential for determining its efficacy and safety profile. As with many targeted therapies, the development of Pexmetinib involves careful consideration of potential side effects and interactions with other medications. Ongoing research continues to explore its therapeutic potential and optimal use in combination with other treatments in oncology.

Synonyms:

• Arry-614

Pexmetinib

CAS: 945614-12-0

Formula: C₃₁H₃₃FN₆O₃

Purity: 99%

Color and Shape: Solid

Molecular weight: 556.6305

Ref: IN-DA01E5Z7

Pexmetinib

CAS: 945614-12-0

Pexmetinib

Purity: ≥98%

Molecular weight: 556.63g/mol

Ref: 54-BUP13054

Pexmetinib

CAS: 945614-12-0

Pexmetinib (ARRY-614) is an orally bioavailable dual p38 MAPK/Tie-2 inhibitor.Cost-effective and quality-assured.

Formula: C₃₁H₃₃FN₆O₃

Purity: 99.07% - 99.66%

Color and Shape: Solid

Molecular weight: 556.63

Ref: TM-T6934

Pexmetinib

Controlled Product

CAS: 945614-12-0

Applications Pexmetinib is a potent and orally bioavailable dual p38 MAPK/Tie-2 inhibitor preventing tumor growth.
References Garcia-Manero, G. et al.: Clin. Canc. Res., 21, 985 (2015);

Formula: C₃₁H₃₃FN₆O₃

Color and Shape: Neat

Molecular weight: 556.63

Ref: TR-P293620